#77 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
As cannabis use rises among older adults, clinicians need updated knowledge about drug interactions with common medications (anticoagulants, sedatives, statins) and potential adverse effects like falls and cognitive changes that disproportionately affect this population. This trend shifts cannabis from a fringe consideration to a mainstream clinical issue requiring routine screening and counseling in geriatric practice. Understanding patient motivations and efficacy for conditions like chronic pain and insomnia allows clinicians to provide evidence-based guidance rather than defaulting to outdated prohibitionist stances.
A recent study published in JAMA Internal Medicine found that medical cannabis use is rising substantially among older adults, a demographic traditionally underrepresented in cannabis medicine research and clinical practice. The research, conducted by investigators at NYU and UC San Diego, documents shifting patterns of cannabis adoption in aging populations, likely driven by growing legalization, perceived safety relative to opioids, and potential therapeutic benefits for conditions common in older age such as chronic pain, insomnia, and nausea. This trend has important clinical implications as older adults may have greater vulnerability to cannabis-related adverse effects due to polypharmacy, altered pharmacokinetics, and age-related changes in cannabinoid sensitivity and cognitive reserve. Clinicians caring for older patients should be prepared to discuss cannabis use, understand potential drug interactions particularly with medications affecting cytochrome P450 metabolism, and assess risks such as falls, cognitive effects, and cardiovascular complications that may be more pronounced in this population. For prescribers in cannabis-legal jurisdictions, this data underscores the need for evidence-based guidance and geriatric-specific dosing recommendations currently lacking in the literature. Clinicians should routinely inquire about cannabis use in older adult patients and counsel on safe dosing, drug interactions, and monitoring parameters to optimize therapeutic benefit while minimizing harm.
“We’re seeing this uptick in older adults using cannabis, and while the JAMA Internal Medicine data helps us understand the trend, we still need robust evidence on long-term safety and efficacy in this population, particularly around drug interactions and fall risk. The conversation with my older patients is becoming less about whether cannabis might help and more about ensuring we monitor them carefully if they choose to use it.”
💊 The rising prevalence of cannabis use among older adults documented in recent epidemiologic data presents clinicians with an important clinical and counseling challenge, particularly given the limited high-quality evidence on efficacy and safety in this population. Older adults may turn to cannabis for pain, insomnia, or anxiety management, yet they face distinct pharmacokinetic vulnerabilities including altered drug metabolism, polypharmacy interactions, and increased fall and cardiovascular risks that differ from younger populations. The gap between growing patient interest and robust evidence remains substantial, with most cannabis research excluding older adults or lacking rigorous design, making it difficult to provide evidence-based guidance on dose, formulation, or duration of use. Clinicians should routinely ask older patients about cannabis use during substance history assessments, document baseline cognitive and functional status, monitor for adverse effects, and counsel on realistic efficacy expectations and potential drug interactions, while recognizing that some patients may have already made informed
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
